These differences correlated with OVA-specific CTLs and CTLeff, which were >tenfold higher in the blood of artLCMV-OVA-treated wt mice than in analogously treated Il1rl1−/− mice (Supplementary Fig. 5c), altogether attesting to the critical function of the IL-33–ST2 axis in artLCMV-based cancer immunotherapy. The gene discussed is IL1RL1; the disease is cancer.